Blake Borgeson - 04 Aug 2026 Form 4 Insider Report for RECURSION PHARMACEUTICALS, INC. (RXRX)

Reporting relationship: Director
Issuer ticker: RXRX
Reported as of: 04 Aug 2026
Net transaction value: -$97,500
SEC form: 4
Accepted by SEC: 06 Aug 2026, 17:09:25 UTC
Prior SEC filing: 09 Jul 2026
Source filing: View source filing
Reporting owner signature: /s/Jonathan Golightly, attorney-in-fact

Key filing fact

Blake Borgeson filed Form 4 for RECURSION PHARMACEUTICALS, INC. (RXRX) on 06 Aug 2026.

Key facts

This page summarizes Blake Borgeson's Form 4 filing for RECURSION PHARMACEUTICALS, INC. (RXRX).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 06 Aug 2026, 17:09.

Change

Previous filing in this sequence was filed on 09 Jul 2026.
Current net transaction value: -$97,500.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001856094 Primary reporting owner

Borgeson Blake

Relationship: Director
Address: C/O RECURSION PHARMACEUTICALS, 41 S. RIO GRANDE STREET, SALT LAKE CITY
Signature: /s/Jonathan Golightly, attorney-in-fact
Signature date: 06 Aug 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

RXRX transaction

Class A Common Stock

Sale

Transaction value: $97,500
Shares: -30,000
Change %: -0.48%
Price: $3.25
Shares after: 6,188,287
Date: 04 Aug 2026
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 1 footnote

Footnote F1

This transaction is pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 31, 2025.